Skip to main content

Simulations Plus, Inc.

corporate_fare Company Profile

Simulations Plus, Inc.

SLP·NASDAQ·Technology·CIK 0001023459

Simulations Plus, Inc. is a global leader and premier provider in the biopharma sector, incorporated in California on July 17, 1996. The Company offers advanced software and consulting services that enhance drug discovery and development, clinical trial operations, and commercialization. Simulations Plus supports clients across the drug development lifecycle, from early discovery through all phases of clinical research and development (R&D), including clinical operations, to product commercialization. The Company serves clients as a strategic partner, offering solutions that integrate scientific software platforms, artificial intelligence-augmented insights, and expert consulting. Simulations Plus's model-informed drug development (MIDD) software and services solutions allow clients to use modeling and simulation to accelerate the drug development timeline, minimize animal testing, reduce R&D costs, comply with regulatory guidance and best practices, and increase confidence in drug safety and efficacy. The Company's clinical operations solutions support the success of clinical trials by enhancing participant diversity and retention, and driving competency and compliance with trial protocols. Additionally, its commercialization solutions provide support in obtaining regulatory approval and post-regulatory commercialization of new treatments. The Company's mission is to create value for clients by accelerating and reducing R&D costs through innovative science-based software and consulting solutions.

Simulations Plus, Inc. (NASDAQ:SLP) is a publicly traded company in the Technology sector. Wiseek has independently scored 15 items for SLP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-06, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 10/10, with 8 rated 8 or above. Recent SEC coverage for SLP spans DEFA14A, 10-Q, PREM14A, 8-K.

Recent high-impact activity:

  • Altaris Completes $375M Acquisition of Simulations Plus; Stock to Delist
  • Simulations Plus Discloses Merger Litigation and Supplemental Valuation Details Ahead of Aug 27 Vote
  • HSR Waiting Period Expires for Altaris' $375M Acquisition of Simulations Plus
  • Simulations Plus Q3 Revenue Climbs 7%, Net Income Swings to $3.6M; Altaris Merger at $18.50/Share Disclosed
  • Simulations Plus Posts Q3 EPS of 18c Amid Pending $375M Buyout

Financial Snapshot

Fiscal year ended August 31, 2025
Revenue
$79.18M
Net Income
-$64.72M
Diluted EPS
-$3.22
Op. Cash Flow
$18.13M
Free Cash Flow
$17.41M
Gross Profit
$46.22M
Operating Income
-$70.73M
Cash & Equivalents
$30.85M
Debt / Equity
0.00×
Net Margin
-81.7%
Shares Outstanding
20.14M sh
Source: 10-K · filed 2025-12-01 · accession 0001023459-25-000060
Browse all tickers starting with S →

No longer listed

SLP (Simulations Plus, Inc.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. Simulations Plus, Inc was acquired by Altaris. The filings and coverage below remain available as an archive.

feed SLP - Latest Insights

SLP
Oct 06, 2026, 9:15 AM EDT
Source: BusinessWire
Importance Score:
7
SLP
Aug 21, 2026, 6:04 AM EDT
Filing Type: DEFA14A
Importance Score:
7
SLP
Aug 13, 2026, 5:24 PM EDT
Source: Reuters
Importance Score:
7
SLP
Jul 09, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
7
SLP
Jul 09, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
SLP
Jul 09, 2026, 4:01 PM EDT
Filing Type: PREM14A
Importance Score:
9
SLP
Jun 17, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
10
SLP
Jun 16, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
10
SLP
Jun 16, 2026, 9:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
10
SLP
Jun 08, 2026, 8:17 AM EDT
Source: PR Newswire
Importance Score:
8
SLP
Apr 10, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
7
SLP
Apr 09, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
SLP
Apr 09, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
SLP
Feb 18, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
SLP
Jan 09, 2026, 4:07 PM EST
Filing Type: 10-Q
Importance Score:
8
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets